Here's your news in brief: It was by far the US Food and Drug Administration's busiest week of the year for novel drug approvals with five such products getting the green light from the agency: Genentech Inc.'s Rozlytrek (entrectinib), Celgene Corp.'s Inrebic (fedratinib), the Global Alliance for TB Drug Development's pretomanid, Harmony Biosciences LLC’s Wakix (pitolisant) and AbbVie Inc.’s Rinvoq (upadacitinib).
Keeping Track: A Quintet Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
More from Approvals
More from Product Reviews
• By
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
• By
Sanofi’s Dupixent, Amgen’s Uplizna, and Bristol’s Opdivo seek new indications, while J&J hopes to start a franchise with nipocalimab and Stealth’s day of reckoning approaches.
• By
The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.